CalciMedica Inc. (NASDAQ:CALC) Sees Large Decrease in Short Interest

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 323,241 shares, a decrease of 35.7% from the July 30th total of 503,070 shares. Based on an average trading volume of 320,704 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.3% of the company’s shares are short sold.

Wall Street Analyst Weigh In

CALC has been the subject of several research analyst reports. Wall Street Zen upgraded CalciMedica to a “sell” rating in a research report on Saturday, August 22nd. Guggenheim began coverage on shares of CalciMedica in a report on Thursday, August 20th. They issued a “buy” rating for the company. UBS Group restated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $50.00.

Insiders Place Their Bets

In other news, Director Fred A. Middleton acquired 49,794 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was acquired at an average price of $4.00 per share, with a total value of $199,176.00. Following the completion of the purchase, the director directly owned 212,654 shares in the company, valued at approximately $850,616. This trade represents a 30.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 28.25% of the stock is owned by company insiders.

Institutional Investors Weigh In On CalciMedica

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in CalciMedica in the 4th quarter valued at about $127,000. Cetera Investment Advisers boosted its holdings in shares of CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of CalciMedica in the fourth quarter valued at approximately $506,000. Renaissance Technologies LLC increased its holdings in shares of CalciMedica by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares in the last quarter.

CalciMedica Trading Down 6.5%

Shares of NASDAQ:CALC opened at $2.00 on Wednesday. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The firm has a market capitalization of $13.66 million, a price-to-earnings ratio of -0.29 and a beta of 0.91. CalciMedica has a 1 year low of $2.00 and a 1 year high of $36.00. The business’s 50 day moving average price is $3.67 and its 200-day moving average price is $3.49.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, August 11th. The company reported ($2.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.83). On average, equities research analysts forecast that CalciMedica will post -5.25 earnings per share for the current fiscal year.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.